The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models

ROS1 gene rearrangement was observed in around 1–2 % of NSCLC patients and in several other cancers such as cholangiocarcinoma, glioblastoma, or colorectal cancer. Crizotinib, an ALK/ROS1/MET inhibitor, is highly effective against ROS1-rearranged lung cancer and is used in clinic. However, crizotini...

Descripción completa

Detalles Bibliográficos
Autores principales: Katayama, Ryohei, Gong, Bo, Togashi, Noriko, Miyamoto, Masaya, Kiga, Masaki, Iwasaki, Shiho, Kamai, Yasuki, Tominaga, Yuichi, Takeda, Yasuyuki, Kagoshima, Yoshiko, Shimizu, Yuki, Seto, Yosuke, Oh-hara, Tomoko, Koike, Sumie, Nakao, Naoki, Hanzawa, Hiroyuki, Watanabe, Kengo, Yoda, Satoshi, Yanagitani, Noriko, Hata, Aaron N., Shaw, Alice T., Nishio, Makoto, Fujita, Naoya, Isoyama, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6688997/
https://www.ncbi.nlm.nih.gov/pubmed/31399568
http://dx.doi.org/10.1038/s41467-019-11496-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6688997/
https://www.ncbi.nlm.nih.gov/pubmed/31399568
http://dx.doi.org/10.1038/s41467-019-11496-z

Ejemplares similares